{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:35:23Z","timestamp":1793831723646,"version":"4.6.1"},"reference-count":19,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"\n Importance<\/jats:title>\n Cisplatin-associated acute kidney injury (CP-AKI) is a frequent complication of cisplatin chemotherapy and is associated with considerable morbidity and mortality. Prophylactic administration of intravenous (IV) magnesium attenuates CP-AKI in animal models; however, its association with CP-AKI in humans has not been rigorously evaluated.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association of prophylactic IV magnesium administration with CP-AKI in patients with cancer undergoing cisplatin chemotherapy.<\/jats:p>\n <\/jats:sec>\n \n Design, Settings, and Participants<\/jats:title>\n This multicenter study was conducted at 5 major cancer centers across the US and included adult patients with cancer who were treated with a first dose of IV cisplatin between 2006 to 2022. Data analyses were performed from February to December 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n IV magnesium vs no IV magnesium receipt on the first day of cisplatin treatment.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Composite outcome of CP-AKI or death, with CP-AKI defined as a 2-fold or greater increase in serum creatinine levels from baseline or receipt of kidney replacement therapy within 14 days after first dose of IV cisplatin. Secondary outcomes were CP-AKI or death, defined using alternative definitions, as well as major adverse kidney events at 90 days. Inverse probability treatment weighting was used to estimate the association between IV magnesium receipt and CP-AKI. Models were adjusted for demographics, comorbidities, laboratory values, receipt of concurrent nephrotoxic anticancer therapies, site, year of cisplatin administration, and cisplatin dose.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 13\u202f719 patients were included (median [IQR] age, 59 [49-67] years; 7817 male [57%]), of whom 3893 (28.4%) received IV magnesium on the first day of cisplatin chemotherapy. The median (IQR) dose of IV magnesium was 2 (1-2) g. CP-AKI or death occurred in 104 of 3893 patients (2.7%) who received IV magnesium, and in 520 of 9826 (5.3%) who did not (adjusted odds ratio, 0.80; 95% CI, 0.66-0.97). Results were similar across a number of sensitivity analyses and secondary outcomes, including major adverse kidney events at 90 days.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This multicenter cohort study found that patients with cancer who received prophylactic IV magnesium before initiating treatment with IV cisplatin had a lower risk of CP-AKI compared to those who did not receive magnesium. Randomized clinical trials are needed to confirm these findings.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.0756","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T11:31:11Z","timestamp":1745494271000},"page":"636","source":"Crossref","is-referenced-by-count":34,"title":["Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury"],"prefix":"10.1001","volume":"11","author":[{"given":"Shruti","family":"Gupta","sequence":"first","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Adult Survivorship Program, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya G.","family":"Glezerman","sequence":"additional","affiliation":[{"name":"Renal Service, Memorial Sloan Kettering Cancer Center and Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie S.","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Northwell Health, New Hyde Park, New York"},{"name":"Division of Kidney Diseases and Hypertension, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Great Neck, New York"},{"name":"Clinical Digital Solutions, Northwell Health, Lake Success, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Api","family":"Chewcharat","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia L.","family":"Wells","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Ortega","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pirovano","sequence":"additional","affiliation":[{"name":"Adult Survivorship Program, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenar D.","family":"Jhaveri","sequence":"additional","affiliation":[{"name":"Northwell Health, New Hyde Park, New York"},{"name":"Division of Kidney Diseases and Hypertension, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Great Neck, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valda D.","family":"Page","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Section of Nephrology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"Abramson","sequence":"additional","affiliation":[{"name":"Renal Service, Memorial Sloan Kettering Cancer Center and Department of Medicine, Weill Cornell Medical College, New York, New York"},{"name":"Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anip","family":"Bansal","sequence":"additional","affiliation":[{"name":"Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus Aurora, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avisek","family":"Ghimire","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie S.","family":"Joy","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala","family":"Abudayyeh","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Section of Nephrology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Leaf","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"coi250012r1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10147-024-02489-0","article-title":"Magnesium supplementation therapy to prevent cisplatin-induced acute nephrotoxicity in pediatric cancer: a randomized phase-2 trial.","volume":"29","author":"Matsui","year":"2024","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"coi250012r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100351","article-title":"Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study).","volume":"7","author":"Suppadungsuk","year":"2022","journal-title":"ESMO Open"},{"issue":"5","key":"coi250012r3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/MPH.0000000000001159","article-title":"Kidney-protective effect of magnesium supplementation in cisplatin-containing chemotherapy for pediatric cancer: a retrospective study.","volume":"40","author":"Matsui","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"coi250012r4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40463-018-0261-3","article-title":"Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer.","volume":"47","author":"Kimura","year":"2018","journal-title":"J Otolaryngol Head Neck Surg"},{"issue":"4","key":"coi250012r5","doi-asserted-by":"publisher","first-page":"F369","DOI":"10.1152\/ajprenal.00127.2014","article-title":"Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation.","volume":"307","author":"Solanki","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"coi250012r6","doi-asserted-by":"publisher","first-page":"F35","DOI":"10.1152\/ajprenal.00096.2015","article-title":"Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice.","volume":"309","author":"Solanki","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"coi250012r7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ejphar.2017.05.034","article-title":"Magnesium attenuates cisplatin-induced nephrotoxicity by regulating the expression of renal transporters.","volume":"811","author":"Saito","year":"2017","journal-title":"Eur J Pharmacol"},{"issue":"21","key":"coi250012r8","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1056\/NEJMp2407586","article-title":"\u201cTarget trial emulation\u201d for observational studies: potential and pitfalls.","volume":"391","author":"Hubbard","year":"2024","journal-title":"N Engl J Med"},{"key":"coi250012r9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-077169","article-title":"Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study.","volume":"384","author":"Gupta","year":"2024","journal-title":"BMJ"},{"key":"coi250012r10","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.1","article-title":"Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury.","author":"Kellum","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"19","key":"coi250012r11","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin c-based equations to estimate GFR without race.","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"coi250012r12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142225","article-title":"Understanding the risk factors and long-term consequences of cisplatin-associated acute kidney injury: an observational cohort study.","volume":"10","author":"Bhat","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"coi250012r13","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.2018.21554","article-title":"Using the E-value to assess the potential effect of unmeasured confounding in observational studies.","volume":"321","author":"Haneuse","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"coi250012r14","doi-asserted-by":"publisher","first-page":"F339","DOI":"10.1152\/ajprenal.00688.2016","article-title":"Magnesium improves cisplatin-mediated tumor killing while protecting against cisplatin-induced nephrotoxicity.","volume":"313","author":"Kumar","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"coi250012r15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1079\/BJN2001498","article-title":"Increased phagocytosis and production of reactive oxygen species by neutrophils during magnesium deficiency in rats and inhibition by high magnesium concentration.","volume":"87","author":"Bussi\u00e8re","year":"2002","journal-title":"Br J Nutr"},{"issue":"1","key":"coi250012r16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/S0925-4439(01)00089-8","article-title":"Changes in gene expression in rat thymocytes identified by cDNA array support the occurrence of oxidative stress in early magnesium deficiency.","volume":"1586","author":"Petrault","year":"2002","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"coi250012r17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/bjc.1986.147","article-title":"Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial.","volume":"54","author":"Willox","year":"1986","journal-title":"Br J Cancer"},{"issue":"4","key":"coi250012r18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/00000421-199208000-00016","article-title":"Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial.","volume":"15","author":"Martin","year":"1992","journal-title":"Am J Clin Oncol"},{"issue":"17","key":"coi250012r19","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.ejca.2008.08.005","article-title":"Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study.","volume":"44","author":"Bodnar","year":"2008","journal-title":"Eur J Cancer"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2833151\/jamaoncology_gupta_2025_oi_250012_1749251715.54659.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T11:00:37Z","timestamp":1750417237000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2833151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.0756","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}